Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director | June 15, 2017 | June 16, 2017 |
| Impax Laboratories, LLCIPXL · Entity 14052 | Director | May 16, 2017 | May 17, 2017 |
| OptiNose, Inc.OPTN · Entity 79464 | Director | October 12, 2017 | October 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date June 15, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.58 · Expires 2027-06-14 | Direct | 8,000 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 8,000 · Balance 8,000 F1: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date.
Impax Laboratories, LLC
Report date May 16, 2017 · Filed May 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,270 |
Reported balance
After 2017-05-16 transaction · row 1
1 source rowRow 1 · 2017-05-16 · Grant · Acquired 4,375 · Balance 9,270 |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 10,575 |
Reported balance
After 2017-05-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-16 · Grant · Acquired 10,575 · Balance 10,575 F1: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders.
OptiNose, Inc.
Report date October 12, 2017 · Filed October 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2027-10-11 | Direct | 28,879 |
Reported balance
After 2017-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-12 · Grant · Acquired 28,879 · Balance 28,879 F1: The option vests and becomes exercisable over a three-year period commencing on October 12, 2017. Thirty-three percent (33%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable over a three-year period commencing on October 12, 2017. Thirty-three percent (33%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2017 Filed Oct 16, 2017 12:39 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 28,879 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062322 · a4.xml · derivative · entry 1 Bierly Rick · CIK 0001604351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,879 Underlying: Common Stock · 28,879 shares Expires 2027-10-11 F1 · derivative.exercise_date: The option vests and becomes exercisable over a three-year period commencing on October 12, 2017. Thirty-three percent (33%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 19:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.58 | $0.00 |
DisclosureSEC source: 0001209191-17-040674 · doc4.xml · derivative · entry 1 Bierly Rick · CIK 0001604351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:47 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 10,575 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001003642-17-000051 · wf-form4_149505044215091.xml · derivative · entry 2 Bierly Rick · CIK 0001604351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:47 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000051 · wf-form4_149505044215091.xml · nonDerivative · entry 1 Bierly Rick · CIK 0001604351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,270 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.